



<b>Situation Report: Confirmed COVID-19</b>	<b>Location: The Gambia</b>
<b>Date of Report: 1<sup>st</sup> – 6<sup>th</sup> February 2022</b>	<b>Investigation Start Date: 17<sup>th</sup> March 2020 as of 18hrs.</b>
<b>Prepared by: Epidemiology and Disease Control Unit, MoH, The Gambia</b>	

## I. HIGHLIGHTS

This is the 421<sup>st</sup> national situation report since the confirmation of the first case of the coronavirus disease (COVID-19) in The Gambia, on the 16<sup>th</sup> March 2020

- **One (1)** new COVID-19-related death registered, bringing the total to **365 (Crude Case-Fatality Ratio, 3.1%)**
- A total of **31** new cases were registered (**Cumulative cases 11,911**)
- The test positivity rate is **1.9% (31/1652)**, **NPHL –1621 (29 positives)** and **MRCG – 31 (2 Positives)**
  - **One (1)** case are currently on **oxygen therapy**
  - A total of **59** cases were discharged after at least **10** days from the day they tested positive but evaded institutional isolation and **1** from COVID-19 treatment centres
- As of **5<sup>th</sup> February 2022**, the following number of people have been vaccinated with:
  - **Johnson & Johnson:**
    - **Only 1 dose: 283,501**
  - **Sinopharm:**
    - **Dose 1: 4,507**
    - **Dose 2: 3,358**
  - **AstraZeneca:**
    - **Dose 1: 40,680**
    - **Dose 2: 28,692**
- **TARGET POPULATION** (based on microplanning estimates - **1,564,214**)
  - Proportion of target population fully vaccinated (2 doses of AZ/Sinopharm OR 1 dose of J&J): **20.2%**
  - Proportion of target population that received at least one Covid-19 vaccine dose (AZ OR J&J OR Sinopharm): **21.0%**
- **TOTAL POPULATION** (Based on final MoH population projections for 2021 - **2,438,899**)
  - Proportion of total population fully vaccinated (2 doses of AZ/Sinopharm OR 1 dose of J&J): **12.9%**
  - Proportion of total population that received at least one Covid-19 vaccine dose (AZ OR J&J OR Sinopharm): **13.5%**

## COVID-19 SITUATION IN NUMBERS

### Globally

Confirmed Cases: **399,378,340**

Recoveries: **319,192,986**

Deaths: **5,772,985**

### Senegal

Confirmed Cases: **85,256**

Recoveries: **82,463**

Deaths: **1,956**

### The Gambia


Confirmed Cases: **11,911**

Active Cases: **25**

Recoveries: **11,521**


Deaths: **365**

## II. EPIDEMIOLOGICAL DESCRIPTION



**Fig1: Geographic Distribution of COVID-19 Cases per 100,000 Pop. by Region Since the start of the Pandemic to 31<sup>st</sup> December (Number Above) and December only (Number below) 2021 in The Gambia**

- Western 1 Health Region has a disproportionately higher number of cases than all the health regions (**See Fig. 1**)
- Below are the age-sex distribution and the Epi-curve of confirmed cases by date of sample collection, respectively (**See Fig. 2 and 3**)




**Fig 2: Age-Sex Distribution of Confirmed COVID-19 Cases, The Gambia, 2022**

✧ This excludes the 27 confirmed cases whose demographic information are not yet available

About 59% of the confirmed cases are males (**See Fig. 2**)

About 58% of the confirmed cases are 40 years below (**See Fig. 2**)



**Fig. 3: Epidemic Curve of Laboratory-Confirmed Cases Reported daily, COVID-19 Pandemic, The Gambia, 16<sup>th</sup> March 2020-6<sup>th</sup> February 2022\*.**

A considerable amount of time elapsed between date of reporting and the date of laboratory confirmation of some cases

- Three main waves of infection occurred – the pre airport closure wave, the importation from Senegal wave and the intermittent airport re-opening and loosening of restrictions wave

**Table 1: Summary of New and Cumulative Public Health Response Outputs, COVID-19 Pandemic, The Gambia, 2022**

Status	New	Cumulative
No. of active cases in institutional isolation		4
No. of COVID-19 patients on oxygen support		1
No. of patients recovered and discharged	0	
In Hotel Quarantine	0	19
Completed Hotel Quarantine	0	5,240
Completed follow-up (asymptomatic people with travel history to affected countries) *	0	310
No. of Contact(s) Identified**	0	
No. of Contacts being monitored	0	
No. of Contacts who completed 14-day follow-up	0	17,129
No. of Contacts lost to follow-up	0	58
Total Tests conducted (Repeat Tests)***	1652(0)	146,848
Positive test result (Repeat Tests)***	31(0)	11,911
Negative test result (Repeat Tests)***	1621(0)	133,578
Inconclusive test result (Repeat Tests)***	0(0)	

\* Follow-up completed prior to the 17<sup>th</sup> March (when the first confirmed case was reported)

\*\* Includes both low-risk and high-risk contacts and not mutually exclusive with number quarantined (as some have been quarantined)

\*\*\* Includes repeat tests in bracket

Table 2: Covid-19 vaccine Doses administered over the last 10 days by region in The Gambia,2022

Region	25/01/2022	02/02/2022	03/02/2022	Total
CRR	259	0	0	259
LRR	8	0	0	8
NBER	28	0	0	28
NBWR	15	0	0	15
URR	116	0	0	116
WR1	278	49	39	366
WR2	208	0	0	208
<b>Total</b>	<b>912</b>	<b>49</b>	<b>39</b>	<b>1,000</b>

Table 3: Major response activities undertaken newly, COVID-19 Outbreak, The Gambia, 2022

### III. MAJOR RESPONSE ACTIVITIES

Component	Interventions
Coordination	<ul style="list-style-type: none"> <li>Coordination meetings held at central level</li> </ul>
Surveillance/ Laboratory	<ul style="list-style-type: none"> <li>A total of <b>1652</b> new laboratory test results received <b>1621</b> from <b>NPHL</b> and <b>31</b> from <b>MRCG</b> <ul style="list-style-type: none"> <li>Of these, <b>no</b> test result returned inconclusive or indeterminate, <b>31</b> new samples tested positive</li> </ul> </li> </ul>
Case Management / Psychosocial Support & Research / IPC	<ul style="list-style-type: none"> <li><b>One (1)</b> new COVID-19 related death recorded</li> <li><b>One (1)</b> patient was newly discharged from treatment centres</li> <li><b>No</b> new contacts traced and monitored</li> <li><b>One (1)</b> COVID-19 patient is currently on <b>oxygen therapy</b></li> </ul>

### IV. GAPS/CHALLENGES:

- CBS activities not replicated in all regions to increase in the number of daily tests being conducted
- Support for innovative countrywide risk communication strategies and activities on COVID-19 is suboptimal
- Dwindling compliance with mask-wearing requirements
- Low turn-out at COVID-19 sample collection sites resulting in fewer number of daily tests
- Denial, misinformation, stigma and discrimination against COVID-19 affected families.
- Low COVID-19 vaccination coverage rate

## V. NEXT STEPS/RECOMMENDATIONS:

- CBS activities need to be synchronized with MRC’s ILI surveillance to spur up testing rates in the hinterland.
- Strengthen community-based surveillance in all regions to increase awareness and testing rates
- Intensify risk communication and community engagement activities, on COVID-19 at community level, including at LUMOS, in a bid to curtail community transmission and dispel misinformation and denial and vaccine hesitancy
- Thorough enforcement of the mandatory mask-wearing regulation
- IPC measures should be strictly adhered to in all public and private health healthcare facilities
- Provision of adequate stocks of PPEs to all health facilities
- Health workers to observe all COVID-19 preventive measures always including the donning of appropriate PPEs
- Intensify activities geared to increase COVID-19 vaccination coverage at all levels
- Strengthen the capacity of the National Public Health Laboratories to conduct sequencing to identify new variants from positive samples as the COVID-19 virus evolves.

**For comments or questions, please contact:**  
**Amadou Woury Jallow**  
 Public Health Emergency Operations Center  
 Epidemiology and Disease Control Unit, The Gambia  
**Email:** [amadou.jallow@gmail.com](mailto:amadou.jallow@gmail.com) **Phone:** +220 3921415/2639690/9921415

## PARTNERS

